These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 28590819)

  • 1. Pattern and Distribution of Distant Metastases in Anaplastic Prostate Carcinoma: A Single-Institute Experience With 101 Patients.
    Ganeshan D; Aparicio AM; Morani A; Kundra V
    AJR Am J Roentgenol; 2017 Aug; 209(2):327-332. PubMed ID: 28590819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Small cell and anaplastic prostate cancer: correlation between CT findings and prostate-specific antigen level.
    Schwartz LH; LaTrenta LR; Bonaccio E; Kelly WK; Scher HI; Panicek DM
    Radiology; 1998 Sep; 208(3):735-8. PubMed ID: 9722854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atypical metastases from prostate cancer: 10-year experience at a single institution.
    Vinjamoori AH; Jagannathan JP; Shinagare AB; Taplin ME; Oh WK; Van den Abbeele AD; Ramaiya NH
    AJR Am J Roentgenol; 2012 Aug; 199(2):367-72. PubMed ID: 22826398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extent of disease in recurrent prostate cancer determined by [(68)Ga]PSMA-HBED-CC PET/CT in relation to PSA levels, PSA doubling time and Gleason score.
    Verburg FA; Pfister D; Heidenreich A; Vogg A; Drude NI; Vöö S; Mottaghy FM; Behrendt FF
    Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):397-403. PubMed ID: 26563121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinico-pathologic characterisation of metastatic prostate cancer in the Radiotherapy and Oncology Department, Ahmadu Bello University Teaching Hospital, Zaria-Nigeria: 2006-2009.
    Adewuyi SA; Mbibu NH; Samaila MO; Ketiku KK; Durosinmi-Etti FA
    Niger Postgrad Med J; 2013 Mar; 20(1):45-51. PubMed ID: 23661210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. (18)F-choline PET/CT for early detection of metastases in biochemical recurrence following radical prostatectomy.
    Kjölhede H; Ahlgren G; Almquist H; Liedberg F; Lyttkens K; Ohlsson T; Bratt O
    World J Urol; 2015 Nov; 33(11):1749-52. PubMed ID: 25824540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of extraprostatic disease in the staging of prostate cancer by F-18 choline PET/CT: can PSA and PSA density help in patient selection?
    Calabria F; Chiaravalloti A; Tavolozza M; Ragano-Caracciolo C; Schillaci O
    Nucl Med Commun; 2013 Aug; 34(8):733-40. PubMed ID: 23680652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mediastinal lymph node uptake in patients with prostate carcinoma on F18-choline PET/CT.
    Rietbergen DD; van der Hiel B; Vogel W; Stokkel MP
    Nucl Med Commun; 2011 Dec; 32(12):1143-7. PubMed ID: 22045476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical utility of (18)F-fluorocholine positron-emission tomography/computed tomography (PET/CT) in biochemical relapse of prostate cancer after radical treatment: results of a multicentre study.
    Rodado-Marina S; Coronado-Poggio M; García-Vicente AM; García-Garzón JR; Alonso-Farto JC; de la Jara AC; Maldonado-Suárez A; Rodríguez-Fernández A
    BJU Int; 2015 Jun; 115(6):874-83. PubMed ID: 25307619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early biochemical relapse after radical prostatectomy: which prostate cancer patients may benefit from a restaging 11C-Choline PET/CT scan before salvage radiation therapy?
    Castellucci P; Ceci F; Graziani T; Schiavina R; Brunocilla E; Mazzarotto R; Pettinato C; Celli M; Lodi F; Fanti S
    J Nucl Med; 2014 Sep; 55(9):1424-9. PubMed ID: 24935990
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection level and pattern of positive lesions using PSMA PET/CT for staging prior to radiation therapy.
    Schmidt-Hegemann NS; Fendler WP; Buchner A; Stief C; Rogowski P; Niyazi M; Eze C; Li M; Bartenstein P; Belka C; Ganswindt U
    Radiat Oncol; 2017 Nov; 12(1):176. PubMed ID: 29126446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of 18F-choline PET/CT in prostate cancer patients with biochemical recurrence: influence of androgen deprivation therapy and correlation with PSA kinetics.
    Beheshti M; Haim S; Zakavi R; Steinmair M; Waldenberger P; Kunit T; Nader M; Langsteger W; Loidl W
    J Nucl Med; 2013 Jun; 54(6):833-40. PubMed ID: 23559588
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The relationship between the serum level of prostate specific antigen and bone and CT scans in the staging of the primary carcinoma of the prostate].
    Hoefman E; Hulshof MC; de Reijke TM; Bruijnes E; Redekop WK; van Straalen JP
    Ned Tijdschr Geneeskd; 1998 May; 142(20):1142-6. PubMed ID: 9623236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imaging yield from 133 consecutive patients with prostate cancer and low trigger PSA from a single institution.
    Shinagare AB; Keraliya A; Somarouthu B; Tirumani SH; Ramaiya NH; Kantoff PW
    Clin Radiol; 2016 Mar; 71(3):e143-9. PubMed ID: 26767544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The relationship between local recurrences and distant metastases in prostate cancer: can
    Giovacchini G; Ciarmiello A; Giovannini E; Fodor A; Cozzarini C; Mapelli P; Incerti E; Di Muzio N; Gianolli L; Picchio M
    Eur J Nucl Med Mol Imaging; 2018 Jun; 45(6):962-969. PubMed ID: 29453702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 11C-Choline PET/CT in the primary diagnosis of prostate cancer: impact on treatment planning.
    Garcia JR; Jorcano S; Soler M; Linero D; Moragas M; Riera E; Miralbell R; Lomeña F
    Q J Nucl Med Mol Imaging; 2015 Sep; 59(3):342-50. PubMed ID: 24844254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate cancer progression in the presence of undetectable or low serum prostate-specific antigen level.
    Leibovici D; Spiess PE; Agarwal PK; Tu SM; Pettaway CA; Hitzhusen K; Millikan RE; Pisters LL
    Cancer; 2007 Jan; 109(2):198-204. PubMed ID: 17171704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Routine interval computed tomography to detect new soft-tissue disease might be unnecessary in patients with androgen-independent prostate cancer and metastasis only to bone.
    Wu SL; Jones E; Gulley JL; Arlen PM; Chen CC; Figg WD; Dahut WL
    BJU Int; 2007 Mar; 99(3):525-8. PubMed ID: 17155971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of helical computerized tomography, positron emission tomography and monoclonal antibody scans for evaluation of lymph node metastases in patients with prostate specific antigen relapse after treatment for localized prostate cancer.
    Seltzer MA; Barbaric Z; Belldegrun A; Naitoh J; Dorey F; Phelps ME; Gambhir SS; Hoh CK
    J Urol; 1999 Oct; 162(4):1322-8. PubMed ID: 10492189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Seven-month prostate-specific antigen (PSA) is prognostic in patients with prostate cancer initially diagnosed with distant metastases.
    Nieder C; Haukland E; Pawinski A; Norum J
    Med Oncol; 2018 Mar; 35(4):46. PubMed ID: 29508104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.